clinical endpoint was composited of cardiac death, myocardial infarction attributed to the target vessel or TLR. Results: There was no difference in patient baseline characteristics. Lesion length was 11.2AE6.5mm in the DCB-and 12.2AE8.2mm in the POBA-group (p¼n.s). Post PCI, for the stented segment and the total segment minimal lumen diameter and diameter stenosis were not different. Clinical follow-up after 12 months was 100%. Treatment with DCB was superior to balloon angioplasty alone with an in-stent late loss of 0.43AE0.61mm vs. 1.03AE0.77mm (p< 0.001). Minimal lumen diameter was significantly larger and percent diameter stenosis significantly lower with use of the DCB for both the stented and total segment. Restenosis rate was reduced from 58.1% to 17.2% (P< 0.001) and the clinical endpoint at 6 months was reduced from 50% to 16.7% (P< 0.001), respectively. After 12 months the effect of DCB persisted (clinical endpoint 52.6% vs. 16.7%; p< 0.001 and TLR 36.8% vs. 15.3%, p¼0.005), respectively. There was one probable stent thrombosis in the POBA group. Clinical follow-up after 3 years will be completed in June 2014 and presented. Conclusions: Paclitaxel coated balloon angioplasty was superior to balloon angioplasty alone for the treatment of instent-restenosis of drug-eluting stents. Longterm effects of the DCB-therapy after 3 years will be presented.
Background: Previous studies demonstrated that angioplasty with a paclitaxel-coated balloon (PCB) was non-inferior to paclitaxel-eluting stent (PES) implantation when used to treat drug-eluting stent in-stent restenosis (DES-ISR). There is a paucity of data regarding the long-term safety and efficacy of using PCB in treating DES-ISR. We sought to present for the first time the 2-year clinical outcomes from PEPCAD China ISR trial. Methods: PEPCAD China ISR was a 220 patient randomized (1:1), single blind prospective multicenter trial conducted in China. Patients with DES-ISR received either PCB (SeQuentÒ Please, B.Braun Melsungen AG, Germany) or PES (TaxusÒ Liberté, Boston Scientific, Natick, MA, USA) treatment. The primary endpoint was insegment late lumen loss (LLL) at 9 months. Secondary endpoints included 9-month % diameter stenosis (DS), binary restenosis rate, and 1-and 2-year target lesion failure (TLF) defined as the composite of cardiac death, target vessel myocardial infarction or ischemia-driven target lesion revascularization. In addition, definite/probable stent thrombosis (ST) rates were documented. Results: At 9 months, the in-segment LLL, %DS and binary restenosis were not significantly different between PCB and PES group (0.46AE0.51mm vs. 0.55AE0.61mm; 29.0 AE 21.3 vs. 30.8 AE 25.3; 18.6% vs. 23.8%; p>0.05 respectively). No adverse ischemic events occurred between 1 to 2 years in PCB group except 1 nontarget vessel revascularization. However, the rate of all-cause death was statistically lower in the PCB group (0% vs. 4.9%, p¼0.03) compared with PES group at 2 years. Major results are shown in the table.
Conclusions: The prolonged 2-year clinical follow-up showed that there was no newly occurred death, MI, TVR, or ST in PCB group between 1 and 2 years, and statistically, a lower all-cause mortality of PCB compared to PES for the treatment of DES-ISR. (ClinicalTrials.gov identifier: NCT 01622075)
TCT-268
Randomized clinical trial favors the use of drug-coated balloons over plain balloons for the postdilatation of nitinol stents in the SFA and PI segment to lower restenosis rate Josef Tacke 1 , Dominik Kieselbach 2 , Schulte Karl-Ludwig 3 1 Klinikum Passau, Passau, Germany, 2 Eurocor GmbH, Bonn, Germany, 3 1. Charité Berlin, Vascular Center Berlin, Ev. Hospital Königin Elisabeth Herzberge, Berlin, Germany
Background: Stents are needed in up to 50 % of all peripheral interventions where PTA with plain or drug-coated balloons alone will not reopen the vessel sufficiently. Nevertheless, the restenosis rate of stents is still a major limitation of peripheral arterial interventions. Drug-coated balloons potentially overcome the problem of instent restenosis when used for postdilatation after primary nitinol stenting in the SFA and PI segment. Methods: The Freeway Stent Study is a prospective, randomized, international trial started in 15 centers in Germany and Austria. 200 patients will be enrolled and randomized equally to primary nitinol stenting followed by either DCB (FreewayÔ) or plain balloon postdilatation. Primary endpoint is clinically driven target lesion revascularization (TLR) at 6 months, secondary endpoints include further clinical and safety evaluations like shift in Rutherford classification and ABI, LLL, patency rate and MAE. Results: Over 170 patients have been enrolled to date, of which 130 have finished the 6 months and almost 100 the 12 months follow-up. The results highly favor the use of FreewayÔ DCB over plain balloon based on clinically driven TLR (only 3.2 % vs. 10.2 % at 6 months and 8.0 % vs. 17.4 % at 12 months). This is supported by a statistically significant better clinical outcome for PAD patients treated with DCB as postdilatation device regarding primary patency rate, ABI and Rutherford classification at six months. Conclusions: The use of DCB as postdilatation device is investigated in a new approach to decrease the restenosis rate after nitinol stenting in the SFA and PI segment. The latest interim results of the Freeway Stent Study show that DCB might significantly lower the in-stent restenosis rate in the treatment of PAD patients.
TCT-269
Drug-coated balloon vs. standard balloon for the PTA treatment of lesions in the SFA and popliteal artery -First interim results of the FREERIDE study Background: Drug coated balloons (DCB) have provided a new option in the treatment of peripheral artery disease, because they allow elution of an antiproliferative agent into the vessel wall. With the standard methods like the plain old balloon angioplasty (POBA) the effort to restore the normal flow often fails due to restenosis. The FREERIDE study investigates the inhibition of restenosis by the (Paclitaxel) DCB Freeway (Eurocor GmbH, Bonn, Germany) versus standard balloon PTA, in the treatment of de-novo occluded, stenotic or reoccluded lesions in peripheral arteries (SFA and popliteal artery/PI segment). Methods: Controlled multicenter trial conducted in 23 centers worldwide with 280 PAD patients randomized either to Freeway DCB or to POBA. The primary endpoint is the rate of target lesion revascularization (TLR) at 6 months. Further, several secondary endpoints like late lumen loss and patency rate at 6 months, TLR at 12, 24 months follow up (FU), change in the Ankle-brachial index (ABI) and Rutherford classification at FU, and MAE are investigated. Results: Until the date 84 patients have been enrolled, 62 completed the 6 months FU, 8 have not been available for FU. The interim results show that there was remarkably more bail out stenting after POBA compared with Freeway PTA (8.9% vs. 25.6%; p¼0.04). After 6 months there were clear positive trends in the TLR rate for the Freeway arm (5.4% vs. 20%; p¼0.07). MAE were significant lower in the Freeway arm compared to POBA (5.4% vs. 28%; p¼0.01) with 0% vs. 8% death, 0 % both arms for study related amputation and thrombosis. Furthermore there were promising clinical outcomes in Rutherford classification after Freeway vs. POBA. Conclusions: The interim results indicate that the (Paclitaxel)-coated balloon Freeway might provide an advantage for PTA in SFA lesions and PI segment. The drug coated balloons could result in better outcomes overcoming the existing limitations in peripheral artery disease treatment. Death, % (n) 0 (0) 1.9 (2) 0.24 0 (0) 4.9 (5) 0.03
Myocardial Infarction, % (n) 3.7 (4) 6.6 (7) 0.33 3.7 (4) 6.9 (7) 
